Avner Lushi - 20 Feb 2026 Form 4 Insider Report for Silexion Therapeutics Corp (SLXN)

Role
Director
Signature
/s/ Mirit Horenshtein Hadar, Attorney-in-fact
Issuer symbol
SLXN
Transactions as of
20 Feb 2026
Net transactions value
$0
Form type
4
Filing time
23 Feb 2026, 16:06:04 UTC
Previous filing
31 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Lushi Avner Director 5 NARCISSUS BOULEVARD, RAMAT GAN, ISRAEL /s/ Mirit Horenshtein Hadar, Attorney-in-fact 23 Feb 2026 0002033604

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SLXN Ordinary Shares Award $0 +9,091 +56% $0.000000 25,399 20 Feb 2026 By Guangzhou Sino-Israel Biotech Fund F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SLXN Stock Option (right to buy ordinary shares) Award $0 +10,685 $0.000000 10,685 20 Feb 2026 Ordinary Shares 10,685 $1.65 By Guangzhou Sino-Israel Biotech Fund F2, F3, F4
holding SLXN Stock Option (right to buy ordinary shares) 1,872 20 Feb 2026 Ordinary Shares 1,872 $18.90 By Guangzhou Sino-Israel Biotech Fund F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transaction reported in this row consists of the grant to Guangzhou Sino-Israel Biotech Fund ("GIBF") by the Issuer of fully vested restricted share units (RSUs), which were immediately settled for underlying ordinary shares, par value $0.0135 per share ("ordinary shares|), in respect of director services provided by the Reporting Person to the Issuer. The grant was approved by the Issuer's board of directors.
F2 The Reporting Person possesses shared voting and investment authority with respect to the securities reported in this row as a result of his serving as a Managing Partner and CEO of GIBF. The equity interests of GIBF are held by various individuals and entities. The Reporting Person disclaims beneficial ownership of the securities reported in this row except to the extent of his indirect pecuniary interest therein.
F3 The transaction reported in this row consists of the grant to GIBF by the Issuer of options to purchase ordinary shares, for director services provided by the Reporting Person to the Issuer, which grant was approved by the Issuer's board of directors.
F4 The options reported in this row vest in their entirety on the one-year anniversary of, and expire on the ten-year anniversary of, the date of approval of their grant by the Issuer's board of directors.
F5 There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.